Patents by Inventor Tatsumi Yamazaki
Tatsumi Yamazaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965180Abstract: Provided is a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. A human cancer tissue was repeatedly grown in a NOG mouse, separated cancer cells from the grown cancer tissue, and tested and compared various cancer cell culture processes. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process.Type: GrantFiled: August 14, 2020Date of Patent: April 23, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Patent number: 11858987Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.Type: GrantFiled: June 26, 2020Date of Patent: January 2, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20210293769Abstract: Provided are methods for culturing a cancer stem cell-derived tissue, which comprise the step of three-dimensionally culturing a cancer stem cell-derived tissue after treating it with a therapeutic agent for diseases. The culture methods of the present disclosure enable the construction of cell clusters analogous to therapeutic agent-resistant tissues which are characteristically seen in tissues of patients who have actually been administered with a therapeutic agent for diseases. The cell clusters of the present disclosure are useful for elucidating the mechanism for acquiring anticancer agent resistance, identifying a therapeutic target therefor, or screening for a therapeutic agent. The preferred disease in the present disclosure is cancer.Type: ApplicationFiled: August 8, 2019Publication date: September 23, 2021Inventors: Shigeto KAWAI, Masaki YAMAZAKI, Kiyotaka NAKANO, Masami SUZUKI, Tatsumi YAMAZAKI
-
Patent number: 11124773Abstract: The purpose of the present invention is to provide: a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. For achieving the purpose, the present inventors grew a human cancer tissue repeatedly in a NOG mouse, separated cancer cells from the grown cancer tissue, and made a comparison of various cancer cell culture processes with each other. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process, and consequently the present invention has been accomplished.Type: GrantFiled: October 6, 2011Date of Patent: September 21, 2021Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Patent number: 10934351Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.Type: GrantFiled: February 12, 2016Date of Patent: March 2, 2021Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20200385686Abstract: The purpose of the present invention is to provide: a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. For achieving the purpose, the present inventors grew a human cancer tissue repeatedly in a NOG mouse, separated cancer cells from the grown cancer tissue, and made a comparison of various cancer cell culture processes with each other. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process, and consequently the present invention has been accomplished.Type: ApplicationFiled: August 14, 2020Publication date: December 10, 2020Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Publication number: 20200325222Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.Type: ApplicationFiled: June 26, 2020Publication date: October 15, 2020Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
-
Patent number: 10018630Abstract: An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same.Type: GrantFiled: September 7, 2012Date of Patent: July 10, 2018Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, PHARMALOGICALS RESEARCH PTE. LTD.Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20160159904Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.Type: ApplicationFiled: February 12, 2016Publication date: June 9, 2016Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20140314675Abstract: An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same.Type: ApplicationFiled: September 7, 2012Publication date: October 23, 2014Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20140302511Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective of the present invention is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.Type: ApplicationFiled: October 26, 2012Publication date: October 9, 2014Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20130288248Abstract: The purpose of the present invention is to provide: a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. For achieving the purpose, the present inventors grew a human cancer tissue repeatedly in a NOG mouse, separated cancer cells from the grown cancer tissue, and made a comparison of various cancer cell culture processes with each other. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process, and consequently the present invention has been accomplished.Type: ApplicationFiled: October 6, 2011Publication date: October 31, 2013Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, PHARMALOGICALS RESEARCH PTE. LTD.Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Publication number: 20020082396Abstract: The present invention discloses a reshaped human antibody against human IL-8 comprising:Type: ApplicationFiled: December 7, 2000Publication date: June 27, 2002Inventors: Kouji Matsushima, Yoshihiro Matsumoto, Yoshiki Yamada, Koh Sato, Masayuki Tsuchiya, Tatsumi Yamazaki
-
Patent number: 6245894Abstract: A reshaped human antibody is characterized as having the same binding affinity for IL-8 as a chimeric antibody but with low immunogenicity in comparison. The reshaped antibody has the following elements: a human L chain C region or a human L chain FR and an L chain CDR from a mouse monoclonal antibody against human IL-8 and a human H chain C region or a human H chain FR and an H chain CDR of mouse monoclonal antibody against human IL-8. Since the reshaped human antibody has low immunogenicity to humans, it is suitable for use in medical treatment of a variety of medical conditions.Type: GrantFiled: October 12, 1999Date of Patent: June 12, 2001Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kouji Matsushima, Yoshihiro Matsumoto, Yoshiki Yamada, Koh Sato, Masayuki Tsuchiya, Tatsumi Yamazaki
-
Patent number: 6068840Abstract: Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.Type: GrantFiled: July 29, 1997Date of Patent: May 30, 2000Assignee: Chugai Pharmaceutical Co., Ltd.Inventors: Kouji Matsushima, Yoshihiro Matsumoto, Yoshiki Yamada, Koh Sato, Masayuki Tsuchiya, Tatsumi Yamazaki
-
Patent number: 6048972Abstract: Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.Type: GrantFiled: June 20, 1997Date of Patent: April 11, 2000Assignee: Chugai Pharmaceutical Co., Ltd.Inventors: Kouji Matsushima, Yoshihiro Matsumoto, Yoshiki Yamada, Koh Sato, Masayuki Tsuchiya, Tatsumi Yamazaki
-
Patent number: 6024956Abstract: Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.Type: GrantFiled: August 29, 1997Date of Patent: February 15, 2000Assignee: Chugai Pharmaceutical Co., Ltd.Inventors: Kouji Matsushima, Yoshihiro Matsumoto, Yoshiki Yamada, Koh Sato, Masayuki Tsuchiya, Tatsumi Yamazaki
-
Patent number: 5994524Abstract: The present invention discloses a reshaped human antibody against human IL-8 comprising:(A) L chains each comprising:(1) a human L chain C region; and,(2) an L chain V region comprising a human Lchain FR, and an L chain CDR of mouse monoclonal antibody against human IL-8; and,(B) H chains each comprising:(1) a human H chain C region; and,(2) an H chain V region comprising a human Hchain FR, and an H chain CDR of mouse monoclonal antibody against human IL-8. Since the majority of this reshaped human antibody originates in human antibody and the CDR has low antigenicity, the reshaped human antibody of the present invention has low antigenicity to humans, and can therefore be expected to be useful in medical treatment. The present invention further discloses polynucleotides which encode reshaped antibodies against IL-8, as well as host cells and methods to produce these antibodies.Type: GrantFiled: March 7, 1997Date of Patent: November 30, 1999Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kouji Matsushima, Yoshihiro Matsumoto, Yoshiki Yamada, Koh Sato, Masayuki Tsuchiya, Tatsumi Yamazaki